1
|
Abay Z, Sadikalieva S, Shorayeva K, Yespembetov B, Sarmykova M, Jekebekov K, Tokkarina G, Absatova Z, Kalimolda E, Shayakhmetov Y, Moldagulova S, Issabek A, Kopeyev S, Omurtay A, Barakbayev K, Kassenov M, Syrym N, Abduraimov Y, Zakarya K, Nurpeisova A. Phylogenetic analysis of prospective M. bovis antigens with the aim of developing candidate vaccines for bovine tuberculosis. J Genet Eng Biotechnol 2023; 21:99. [PMID: 37823960 PMCID: PMC10570230 DOI: 10.1186/s43141-023-00552-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 09/20/2023] [Indexed: 10/13/2023]
Abstract
BACKGROUND Bovine Tuberculosis is a respiratory disease caused by the pathogen Mycobacterium bovis (M. bovis) that infects cattle. Though rare, this disease can also affect humans, as well as domestic and wild animals, making it a serious concern. Therefore, searching for alternative and new vaccines with high efficiency and safety is the main goal in bovine tuberculosis prophylaxis. New vaccines, known as vector vaccines, have the potential to become safe and effective alternatives to the traditional BCG vaccine. In this study, two major immunodominant proteins of M. bovis Esat-6 and TB10.4 were utilized to create a vector vaccine for bovine tuberculosis. METHODS The Esat-6 and TB10.4 genes were amplified by PCR. The amplified and purified PCR products were sequenced by the Sanger method. Assembly and multiple alignments of amplicon nucleotides were carried out in the MEGA 11 software. RESULT Two genes of the local strain 0078-M. bovis-8/RIBSP were sequenced. The nucleotide sequences were deposited in the GenBank database. Comparative analysis of the nucleotide sequences of the ESAT-6 and TB10.4 genes established 100% identity of the compared strains of Mycobacterium. CONCLUSION Through the use of phylogenetic analysis, it has been confirmed that the amplified genes are related to the mycobacteria genus. This discovery allows the development of a vector vaccine against bovine tuberculosis utilising these genes.
Collapse
Affiliation(s)
- Zhandos Abay
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
- al-Farabi Kazakh National university, Almaty, Kazakhstan
| | | | - Kamshat Shorayeva
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan.
| | - Bolat Yespembetov
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Makpal Sarmykova
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Kuanish Jekebekov
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Gaukhar Tokkarina
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Zharkinay Absatova
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Elina Kalimolda
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Yeraly Shayakhmetov
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Sabina Moldagulova
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Aisha Issabek
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Syrym Kopeyev
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Alisher Omurtay
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Kainar Barakbayev
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Markhabat Kassenov
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Nazym Syrym
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Yergali Abduraimov
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Kunsulu Zakarya
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| | - Ainur Nurpeisova
- Research Institute for Biological Safety Problems, Gvardeysky, 080409, Kazakhstan
| |
Collapse
|
2
|
Abay Z, Nurpeisova A, Shorayeva K, Sadikaliyeva S, Yespembetov B, Syrym N, Sarmykova M, Jekebekov K, Abitayev R, Tokkarina G, Kalimolda E, Absatova Z, Moldagulova S, Yoo HS, Kassenov M, Zakarya K, Abduraimov Y. Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis. Vaccines (Basel) 2023; 11:1199. [PMID: 37515015 PMCID: PMC10385609 DOI: 10.3390/vaccines11071199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 06/30/2023] [Accepted: 07/01/2023] [Indexed: 07/30/2023] Open
Abstract
This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for bovine tuberculosis, using an influenza vector with the NS1 mutation and expressing M. bovis protective antigens ESAT-6 and TB10.4. We vaccinated Balb/c outbred mice two times at 21 days apart. Our experimental design includes mice immunised with the candidate vaccine with or without adjuvant 15% Montanide Gel. The candidate vaccine's safety was determined by biometric analysis, and protective efficacy was assessed by bacteriological and histological experiments following a virulent M. bovis-8 strain challenge. Our data indicated that the adjuvant-free version of the vaccine ensured complete protection from the M. bovis-8 infection in mice.
Collapse
Affiliation(s)
- Zhandos Abay
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
- Department of Biotechnology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
| | - Ainur Nurpeisova
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Kamshat Shorayeva
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | | | - Bolat Yespembetov
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Nazym Syrym
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Makhpal Sarmykova
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Kuanysh Jekebekov
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Ruslan Abitayev
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Gaukhar Tokkarina
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Elina Kalimolda
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Zharkinay Absatova
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Sabina Moldagulova
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Han Sang Yoo
- College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea
| | - Markhabat Kassenov
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Kunsulu Zakarya
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| | - Yergali Abduraimov
- Research Institute for Biological Safety Problems, Guardeyskiy uts 080409, Kazakhstan
| |
Collapse
|
3
|
Ryskeldinova S, Zinina N, Kydyrbayev Z, Yespembetov B, Kozhamkulov Y, Inkarbekov D, Assanzhanova N, Mailybayeva A, Bugybayeva D, Sarmykova M, Khairullin B, Tabynov K, Bulashev A, Aitzhanov B, Abeuov K, Sansyzbay A, Yespolov T, Renukaradhya GJ, Olsen S, Oñate A, Tabynov K. Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies. Front Cell Infect Microbiol 2021; 11:669196. [PMID: 34290993 PMCID: PMC8288105 DOI: 10.3389/fcimb.2021.669196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 06/07/2021] [Indexed: 11/23/2022] Open
Abstract
A novel influenza viral vector based Brucella abortus vaccine (Flu-BA) was introduced for use in cattle in Kazakhstan in 2019. In this study, the safety and efficacy of the vaccine was evaluated in male and female cattle at different ages, and during pregnancy as a part of its registration process. Our data demonstrated that the Flu-BA vaccine was safe after prime or booster vaccination in calves (5–7 months old male and female), heifers (15–17 months old) and cows (6–7 years old) and was not abortogenic in pregnant animals. A mild, localized granuloma was observed at the Flu-BA injection site. Vaccinated animals did not show signs of influenza infection or reduced milk production in dairy cows, and the influenza viral vector (IVV) was not recovered from nasal swabs or milk. Vaccinated animals in all age groups demonstrated increased IgG antibody responses against Brucella Omp16 and L7/L12 proteins with calves demonstrating the greatest increase in humoral responses. Following experimental challenge with B. abortus 544, vaccinates demonstrated greater protection and no signs of clinical disease, including abortion, were observed. The vaccine effectiveness against B. abortus 544 infection was 75, 60 and 60%, respectively, in calves, heifers and adult cows. Brucella were not isolated from calves of vaccinated cattle that were experimentally challenged during pregnancy. Our data suggests that the Flu-BA vaccine is safe and efficacious in cattle, including pregnant animals; and can therefore be administered to cattle of any age.
Collapse
Affiliation(s)
- Sholpan Ryskeldinova
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Nadezhda Zinina
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Zhailaubay Kydyrbayev
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Bolat Yespembetov
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Yerken Kozhamkulov
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Dulat Inkarbekov
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Nurika Assanzhanova
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Aigerim Mailybayeva
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Dina Bugybayeva
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan.,International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Makhpal Sarmykova
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Berik Khairullin
- Infectious Disease Monitoring Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Kairat Tabynov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan.,Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan
| | - Aitbay Bulashev
- Department of Microbiology and Biotechnology, S. Seifullin Kazakh Agrotechnical University, Nur-Sultan, Kazakhstan
| | - Batyrbek Aitzhanov
- Department of Clinical Veterinary Medicine, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Khairulla Abeuov
- Infectious Disease Monitoring Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Abylay Sansyzbay
- Department of Biological Safety, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Tlektes Yespolov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Gourapura J Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, OH, United States
| | - Steven Olsen
- Independent Researcher, McCallsburg, IA, United States
| | - Angel Oñate
- Laboratory of Molecular Immunology, Department of Microbiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| | - Kaissar Tabynov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan.,Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan
| |
Collapse
|
4
|
Bugybayeva D, Kydyrbayev Z, Zinina N, Assanzhanova N, Yespembetov B, Kozhamkulov Y, Zakarya K, Ryskeldinova S, Tabynov K. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model. Infect Dis Poverty 2021; 10:13. [PMID: 33593447 PMCID: PMC7886305 DOI: 10.1186/s40249-021-00801-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 01/29/2021] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND A new candidate vector vaccine against human brucellosis based on recombinant influenza viral vectors (rIVV) subtypes H5N1 expressing Brucella outer membrane protein (Omp) 16, L7/L12, Omp19 or Cu-Zn SOD proteins has been developed. This paper presents the results of the study of protection of the vaccine using on guinea pigs, including various options of administering, dose and frequency. Provided data of the novel vaccine candidate will contribute to its further movement into the preclinical stage study. METHODS General states of guinea pigs was assessed based on behavior and dynamics of a guinea pig weight-gain test. The effectiveness of the new anti-brucellosis vector vaccine was determined by studying its protective effect after conjunctival, intranasal and sublingual administration in doses 105 EID50, 106 EID50 and 107 EID50 during prime and boost vaccinations of animals, followed by challenge with a virulent strain of B. melitensis 16 M infection. For sake of comparison, the commercial B. melitensis Rev.1 vaccine was used as a control. The protective properties of vaccines were assessed by quantitation of Brucella colonization in organs and tissues of infected animals and compared to the control groups. RESULTS It was observed a gradual increase in body weight of guinea pigs after prime and booster immunization with the vaccine using conjunctival, intranasal and sublingual routes of administration, as well as after using various doses of vaccine. The most optimal way of using the vaccine has been established: double intranasal immunization of guinea pigs at a dose of 106 EID50, which provides 80% protection of guinea pigs from B. melitensis 16 M infection (P < 0.05), which is comparable to the results of the effectiveness of the commercial B. melitensis Rev.1 vaccine. CONCLUSIONS We developed effective human vaccine candidate against brucellosis and developed its immunization protocol in guinea pig model. We believe that because of these studies, the proposed vaccine has achieved the best level of protection, which in turn provides a basis for its further promotion.
Collapse
Affiliation(s)
- Dina Bugybayeva
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Zhailaubay Kydyrbayev
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Nadezhda Zinina
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Nurika Assanzhanova
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Bolat Yespembetov
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Yerken Kozhamkulov
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Kunsulu Zakarya
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan
| | - Sholpan Ryskeldinova
- Research Institute for Biological Safety Problems, 15 Momushuly, Gvardeyskiy, 080409, Kazakhstan.
| | - Kaissar Tabynov
- Kazakh National Agrarian University, 8 Abay Avenue, Almaty, 050010, Kazakhstan. .,Research Institute of Cardiology and Internal Medicine, 120 Aiteke bi, Almaty, 050000, Kazakhstan.
| |
Collapse
|
5
|
Mailybayeva A, Yespembetov B, Ryskeldinova S, Zinina N, Sansyzbay A, Renukaradhya GJ, Petrovsky N, Tabynov K. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PLoS One 2017; 12:e0186484. [PMID: 29023541 PMCID: PMC5638537 DOI: 10.1371/journal.pone.0186484] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2017] [Accepted: 10/02/2017] [Indexed: 01/26/2023] Open
Abstract
We previously developed a potent candidate vaccine against bovine brucellosis caused by Brucella abortus using the influenza viral vector expressing Brucella Omp16 and L7/L12 proteins (Flu-BA). Our success in the Flu-BA vaccine trial in cattle and results of a pilot study in non-pregnant small ruminants prompted us in the current study to test its efficacy against B. melitensis infection in pregnant sheep and goats. In this study, we improved the Flu-BA vaccine formulation and immunization method to achieve maximum efficacy and safety. The Flu-BA vaccine formulation had two additional proteins Omp19 and SOD, and administered thrice with 20% Montanide Gel01 adjuvant, simultaneously by both subcutaneous and conjunctival routes at 21 days intervals in pregnant sheep and goats. At 42 days post-vaccination (DPV) we detected antigen-specific IgG antibodies predominantly of IgG2a isotype but also IgG1, and also detected a strong lymphocyte recall response with IFN-γ production. Importantly, our candidate vaccine prevented abortion in 66.7% and 77.8% of pregnant sheep and goats, respectively. Furthermore, complete protection (absence of live B. melitensis 16M) was observed in 55.6% and 66.7% of challenged sheep and goats, and 72.7% and 90.0% of their fetuses (lambs/yeanlings), respectively. The severity of B. melitensis 16M infection in vaccinated sheep and goats and their fetuses (index of infection and rates of Brucella colonization in tissues) was significantly lower than in control groups. None of the protection parameters after vaccination with Flu-BA vaccine were statistically inferior to protection seen with the commercial B. melitensis Rev.1 vaccine (protection against abortion and vaccination efficacy, alpha = 0.18–0.34, infection index, P = 0.37–0.77, Brucella colonization, P = 0.16 to P > 0.99). In conclusion, our improved Flu-BA vaccine formulation and delivery method were found safe and effective in protecting pregnant sheep and goats against adverse consequences of B. melitensis infection.
Collapse
Affiliation(s)
- Aigerim Mailybayeva
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Bolat Yespembetov
- Laboratory of Microbiology, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Sholpan Ryskeldinova
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Nadezhda Zinina
- Laboratory of Microbiology, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Abylai Sansyzbay
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Gourapura J. Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, United States of America
| | | | - Kaissar Tabynov
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
- Vaxine Pty Ltd and Flinders University, Bedford Park, Australia
- * E-mail: ,
| |
Collapse
|
6
|
Tabynov K, Yespembetov B, Matikhan N, Ryskeldinova S, Zinina N, Kydyrbayev Z, Assanzhanova N, Tabynov K, Renukaradhya GJ, Mukhitdinova G, Sansyzbay A. First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection. Vet Microbiol 2016; 197:15-20. [PMID: 27938677 DOI: 10.1016/j.vetmic.2016.11.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 10/31/2016] [Accepted: 11/01/2016] [Indexed: 01/22/2023]
Abstract
Previously we developed and evaluated a candidate influenza viral vector based Brucella abortus vaccine (Flu-BA) administered with a potent adjuvant Montanide Gel01 in cattle, which was found safe and highly effective. This study was aimed to establish a proof-of-concept of the efficacy of Flu-BA vaccine formulation in sheep and goats. We vaccinated sheep and goats with Flu-BA vaccine and as a positive control vaccinated a group of animals with a commercial B. melitensis Rev.1 vaccine. Clinically, both Flu-BA and Rev.1 vaccines were found safe. Serological analysis showed the animals received Flu-BA vaccine did not induce antibody response against Brucella Omp16 and L7/L12 proteins during the period of our study (56days post-initial vaccination, PIV). But observed significant antigen-specific T cell response indicated by increased lymphocyte stimulation index and enhanced secretion of IFN-γ at day 56 PIV in Flu-BA group. The Flu-BA vaccinated animals completely protected 57.1% of sheep and 42.9% of goats against B. melitensis 16M challenge. The severity of brucellosis in terms of infection index and colonization of Brucella in tissues was significantly lower in the Flu-BA group compared to negative control animals group. Nevertheless, positive control commercial Rev.1 vaccine provided strong antigen-specific T cell immunity and protection against B. melitensis 16M infection. We conclude that the Flu-BA vaccine induces a significant antigen-specific T-cell response and provides complete protection in approximately 50% of sheep and goats against B. melitensis 16M infection. Further investigations are needed to improve the efficacy of Flu-BA and explore its practical application in small ruminants.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan.
| | - Bolat Yespembetov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nurali Matikhan
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Sholpan Ryskeldinova
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nadezhda Zinina
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Zhailaubay Kydyrbayev
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nurika Assanzhanova
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Kairat Tabynov
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Gourapura J Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, OH 44691, USA
| | - Gulnara Mukhitdinova
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Abylai Sansyzbay
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| |
Collapse
|
7
|
Tabynov K, Yespembetov B, Ryskeldinova S, Zinina N, Kydyrbayev Z, Kozhamkulov Y, Inkarbekov D, Sansyzbay A. Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection. Vaccine 2015; 34:438-444. [PMID: 26709638 DOI: 10.1016/j.vaccine.2015.12.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 12/04/2015] [Accepted: 12/08/2015] [Indexed: 01/29/2023]
Abstract
This study analyzed the duration of the antigen-specific humoral and T-cell immune responses and protectiveness of a recently-developed influenza viral vector Brucella abortus (Flu-BA) vaccine expressing Brucella proteins Omp16 and L7/L12 and containing the adjuvant Montadine Gel01 in cattle. At 1 month post-booster vaccination (BV), both humoral (up to 3 months post-BV; GMT IgG ELISA titer 214±55 to 857±136, with a prevalence of IgG2a over IgG1 isotype antibodies) and T-cell immune responses were observed in vaccinated heifers (n=35) compared to control animals (n=35, injected with adjuvant/PBS only). A pronounced T-cell immune response was induced and maintained for 12 months post-BV, as indicated by the lymphocyte stimulation index (2.7±0.4 to 10.1±0.9 cpm) and production of IFN-γ (13.7±1.7 to 40.0±3.0 ng/ml) at 3, 6, 9, and 12 months post-BV. Prime-boost vaccination provided significant protection against B. abortus infection at 3, 6, 9 and 12 months (study duration) post-BV (7 heifers per time point; alpha=0.03-0.01 vs. control group). Between 57.1 and 71.4% of vaccinated animals showed no signs of B. abortus infection (or Brucella isolation) at 3, 6, 9 and 12 months post-BV; the severity of infection, as indicated by the index of infection (P=0.0003 to <0.0001) and rates of Brucella colonization (P=0.03 to <0.0001), was significantly lower for vaccinated diseased animals than appropriate control animals. Good protection from B. abortus infection was also observed among pregnant vaccinated heifers (alpha=0.03), as well as their fetuses and calves (alpha=0.01), for 12 months post-BV. Additionally, 71.4% of vaccinated heifers calved successfully whereas all pregnant control animals aborted (alpha=0.01). Prime-boost vaccination of cattle with Flu-BA induces an antigen-specific humoral and pronounced T cell immune response and most importantly provides good protectiveness, even in pregnant heifers, for at least 12 months post-BV.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan.
| | - Bolat Yespembetov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Sholpan Ryskeldinova
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Nadezhda Zinina
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Zhailaubay Kydyrbayev
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Yerken Kozhamkulov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Dulat Inkarbekov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| | - Abylai Sansyzbay
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeiskiy 080409, Kazakhstan
| |
Collapse
|
8
|
Tabynov K, Yespembetov B, Sansyzbay A. Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: evaluation of protection in pregnant heifers. Vaccine 2014; 32:5889-92. [PMID: 25218295 DOI: 10.1016/j.vaccine.2014.08.073] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 08/13/2014] [Accepted: 08/27/2014] [Indexed: 11/16/2022]
Abstract
The present study provides the first information about the protection of a novel influenza viral vector vaccine expressing the Brucella proteins ribosomal L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with Brucella abortus S19 (n=10) or B. abortus RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Via both the conjunctival or subcutaneous route, evaluation of protectiveness against abortion, effectiveness of vaccination and index of infection (in heifers and their fetuses or calves) demonstrated the vector vaccine provided good protection against B. abortus 544 infection compared to the negative control group (PBS+Montanide Gel01) and comparable protection to commercial vaccines B. abortus S19 or B. abortus RB51.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan.
| | - Bolat Yespembetov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan
| | - Abylai Sansyzbay
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan
| |
Collapse
|
9
|
Tabynov K, Sansyzbay A, Kydyrbayev Z, Yespembetov B, Ryskeldinova S, Zinina N, Assanzhanova N, Sultankulova K, Sandybayev N, Khairullin B, Kuznetsova I, Ferko B, Egorov A. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J 2014; 11:69. [PMID: 24716528 PMCID: PMC3997475 DOI: 10.1186/1743-422x-11-69] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2014] [Accepted: 04/04/2014] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND We generated novel, effective candidate vaccine against Brucella abortus based on recombinant influenza viruses expressing the Brucella ribosomal protein L7/L12 or outer membrane protein (Omp)-16 from the NS1 open reading frame. The main purpose of this work was to evaluate the safety, immunogenicity and protectiveness of vaccine candidate in laboratory animals. METHODS AND RESULTS Four recombinant influenza A viral constructs of the subtypes Н5N1 or H1N1 expressing the Brucella proteins L7/L12 or Omp16 were obtained by a reverse genetics method: Flu-NS1-124-L7/L12-H5N1, Flu-NS1-124-Omp16-H5N1, Flu-NS1-124-L7/L12-H1N1 and Flu-NS1-124-Omp16-H1N1. Despite of substantial modification of NS1 gene, all constructs replicated well and were retain their Brucella inserts over five passages in embryonated chicken eggs (CE). Administration of the mono- or bivalent vaccine formulation via prime-boost intranasal (i.n.), conjunctival (c.) or subcutaneous (s.c.) immunization was safe in mice; no deaths, body weight loss or pathomorphological changes were observed over 56 days. Moreover, guinea pigs vaccinated i.n. with vaccine vectors did not shed the vaccine viruses through their upper respiratory tract after the prime and booster vaccination. These findings confirmed the replication-deficient phenotype of viral vectors. The highest antibody response to Brucella antigen was obtained with constructs expressing L7/L12 (ELISA, GMT 242.5-735.0); whereas the highest T-cell immune response- with construct expressing Omp16 (ELISPOT, 337 ± 52-651 ± 45 spots/4×105cells), which was comparable (P > 0.05) to the response induced by the commercial vaccine B. abortus 19. Interestingly, c. immunization appeared to be optimal for eliciting T-cell immune response. In guinea pigs, the highest protective efficacy after challenge with B. abortus 544 was achieved with Omp16 expressing constructs in both monovalent or bivalent vaccine formulations; protective efficacy was comparable to those induced by a commercial live B. abortus 19 vaccine. CONCLUSION Thus, influenza vectors expressing Brucella protective antigens can be developed as novel influenza vectored vaccine against B. abortus infection.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Republic of Kazakhstan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Tabynov K, Kydyrbayev Z, Ryskeldinova S, Yespembetov B, Zinina N, Assanzhanova N, Kozhamkulov Y, Inkarbekov D, Gotskina T, Sansyzbay A. Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection. Vaccine 2014; 32:2034-41. [PMID: 24598723 DOI: 10.1016/j.vaccine.2014.02.058] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2014] [Revised: 02/04/2014] [Accepted: 02/12/2014] [Indexed: 12/17/2022]
Abstract
This paper presents the results of a study of the immunogenicity and protectiveness of new candidate vector vaccine against Brucella abortus - a bivalent vaccine formulation consisting of a mixture of recombinant influenza A subtype H5N1 or H1N1 (viral constructs vaccine formulation) viruses expressing Brucella ribosomal protein L7/L12 and Omp16, in cattle. To increase the effectiveness of the candidate vaccine, adjuvants such as Montanide Gel01 or chitosan were included in its composition. Immunization of cattle (heifers aged 1-1.5 years, 5 animals per group) with the viral constructs vaccine formulation only, or its combination with adjuvants Montanide Gel01 or chitosan, was conducted via the conjunctival method using cross prime (influenza virus subtype H5N1) and booster (influenza virus subtype H1N1) vaccination schedules at an interval of 28 days. Vaccine candidates were evaluated in comparison with the positive (B. abortus S19) and negative (PBS) controls. The viral constructs vaccine formulations, particularly in combination with Montanide Gel01 adjuvant promoted formation of IgG antibodies (with a predominance of antibodies of isotype IgG2a) against Brucella L7/L12 and Omp16 proteins in ELISA. Moreover, these vaccines in cattle induced a strong antigen-specific T-cell immune response, as indicated by a high number of CD4(+) and CD8(+) cells, as well as the concentration of IFN-γ, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Based on these findings, we recommended the bivalent vaccine formulation containing the adjuvant Montanide Gel01 for practical use in cattle.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan.
| | - Zhailaubay Kydyrbayev
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Sholpan Ryskeldinova
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Bolat Yespembetov
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Nadezhda Zinina
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Nurika Assanzhanova
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Yerken Kozhamkulov
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Dulat Inkarbekov
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Tatyana Gotskina
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| | - Abylai Sansyzbay
- The Research Institute for Biological Safety Problems, 080409, Zhambulskaya oblast, Kordaiskiy rayon, Gvardeisky, Kazakhstan
| |
Collapse
|